Revelation Biosciences (REVB) announces Board retirement

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company’s Board of Directors.

“The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor.”

“The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need,” said Dr. Tidmarsh. “I thank them for their passion and hard work and wish them great success as I look forward to my new projects.” Dr. Tidmarsh informed the Board of Directors that he will be working closely with US governmental agencies in his capacity as Adjunct Professor of Pediatrics and Neonatology at Stanford University School of Medicine and that work may pose a conflict of interest if he were to remain a board member. The company and Dr. Tidmarsh agreed that it would be best to avoid even the appearance of a conflict of interest, hence his retirement from the Revelation Board of Directors.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Meritage Hospitality posts Q2 loss amid restructuring charges
• Cadrenal Therapeutics CMO resigns, separation terms disclosed